Market closedNon-fractional
Jasper Therapeutics/JSPR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Jasper Therapeutics
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
Ticker
JSPR
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Redwood City, United States
Employees
45
Website
www.jaspertherapeutics.com
JSPR Metrics
BasicAdvanced
$321M
Market cap
-
P/E ratio
-$5.52
EPS
2.25
Beta
-
Dividend rate
Price and volume
Market cap
$321M
Beta
2.25
Financial strength
Current ratio
13.493
Quick ratio
13.316
Long term debt to equity
1.372
Total debt to equity
2.255
Management effectiveness
Return on assets (TTM)
-33.05%
Return on equity (TTM)
-53.63%
Valuation
Price to book
2.85
Price to tangible book (TTM)
2.85
Price to free cash flow (TTM)
-4.263
Growth
Earnings per share change (TTM)
-45.18%
3-year earnings per share growth (CAGR)
10.70%
What the Analysts think about JSPR
Analyst Ratings
Majority rating from 8 analysts.
JSPR Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$14M
-16.97%
Profit margin
0.00%
NaN%
JSPR Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.50
-$1.60
-$1.50
-$1.03
-
Expected
-$1.50
-$1.55
-$1.62
-$1.23
-$1.09
Surprise
0.13%
3.06%
-7.12%
-15.92%
-
JSPR News
AllArticlesVideos
Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors
GlobeNewsWire·1 month ago
Jasper Therapeutics to Present at the Oppenheimer Novel Targets in Immunology Summit
GlobeNewsWire·1 month ago
Jasper Therapeutics Presents Data from Preclinical Briquilimab Study at the 2024 EHA Hybrid Congress
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Jasper Therapeutics stock?
Jasper Therapeutics (JSPR) has a market cap of $321M as of July 26, 2024.
What is the P/E ratio for Jasper Therapeutics stock?
The price to earnings (P/E) ratio for Jasper Therapeutics (JSPR) stock is 0 as of July 26, 2024.
Does Jasper Therapeutics stock pay dividends?
No, Jasper Therapeutics (JSPR) stock does not pay dividends to its shareholders as of July 26, 2024.
When is the next Jasper Therapeutics dividend payment date?
Jasper Therapeutics (JSPR) stock does not pay dividends to its shareholders.
What is the beta indicator for Jasper Therapeutics?
Jasper Therapeutics (JSPR) has a beta rating of 2.25. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Jasper Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.